Early Access

Developing the next generation of therapies to combat viral infections

Early Access to pritelivir oral tablets for immunocompromised patients with resistant HSV infections

Aicuris supports expanded access requests for the treatment of eligible patients outside of the Phase 3 clinical trial and collaborates with myTomorrows to facilitate early access to pritelivir for acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. EAPs (also known as “Expanded Access Program” or “Named-Patient Use”) offer an ethical, compliant, and controlled way of providing treatment with a medicine currently not approved in a patient’s country of residence. Eligible patients for an EAP are in high medical need, cannot participate in a clinical trial, and have exhausted all registered treatment options. More information can be requested here.

To get access, patients need to consult with their treating physician to explore all treatment options. If the physician agrees to a treatment with pritelivir oral tablets and to oversee the patient’s treatment, the physician needs to contact the myTomorrows medical team for more information on the EAP. When providing medical information about the patient, please note that only anonymized data shall be included in any patient information. Due to EU data protection law this shall not be accompanied by personal data.